|
Angiotech Pharmaceuticals, Inc.
announced the execution of a
license agreement with Broncus
Technologies, Inc. |
|
06/02/2005 |
|
|
Angiotech Pharmaceuticals, Inc.
(NASDAQ: ANPI, TSX: ANP)
announced the execution of a
license agreement with Broncus
Technologies, Inc. This
agreement allows Broncus
Technologies to incorporate
Angiotech's pioneering
Paclitaxel technology with their
ExhaleR system to treat
emphysema. Emphysema is a
chronic and progressive disease
of lung tissue destruction,
typically as a result of
long-term cigarette smoking. It
now represents the fourth
leading cause of death in the
United States. The ExhaleR
system used in airway bypass
reduces the disabling
hyperinflation in patients with
emphysema by creating
extra-anatomic passages that
allow air to pass from
hyper-inflated areas of the
lungs directly into larger
airways and, ultimately, out of
the body. Preliminary results
suggest that Paclitaxel improves
the duration of benefit of the
airway bypass procedure. PACK-LINk
BioVentures invested in Broncus
Technologies, Inc. |
| ¡@ |
¡@ |
¡@ |
